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     ABSTRACT
Anti-mycobacterial bioactivity of non polar compounds from red algae Euchema spinosum of 
Barang Lompo Island was studied. A triterpenoid carbocylic  acid has been isolated from the 
chloroform fraction of Euchema spinosum, and its structure was determined by spectroscopic 
evidences including IR and 2D NMR and compared to previous data. The isolate was active 
against Mycobacterium tuberculosis at concentration 4 µg/mL, and could also increase the
sensitivity of this pathogen to isoniasid drug. These studies suggest that anti-mycobacterial 
triterpenoid carbocylic  acid in combination with isoniasid may play an important role in host 
defence against M. tuberculosis strain H37Rv.
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INTRODUCTION
Tuberculosis is a chronic infectious disease
and is one of the major enemies of humanity 
from times immemorial. Today it still remains 
as one of the most serious of medical and 
social problems. According to estimation by the 
World Health Organization (WHO), 
approximately one third of the world’s 
population is infected with Mycobacterium 
tuberculosis, eight million people develop 
tuberculosis disease annually, while two million 
people die and another three million new cases
are being added each year1 (WHO, 2008). The 
advances in the chemotherapy of tuberculosis 
in the last-20th century have recently given way 
to anxiety over the evolution of drug resistance 
based on the genetically fixed mutations of M. 
tuberculosis. Moreover, nearly all drugs used 
for the treatment of tuberculosis and 
possessing different mechanisms of activity are
able to cause adverse side effects on humans2. 
Therefore, it is extremely important to search 
for new, low-toxic substances superior to the
available drugs in their activity and efficiency. 
This primarily concerns agents possessing 
activity against M. tuberculosis strains with 
multidrug resistance. Modern tuberculosis is 
generally associated with M. tuberculosis and
M. bovis, mycobacteria that are pathogenic to 
humans. Because of slow growth and 
pathogenicity of M. tuberculosis H37Rv, many 
research groups use fast-growing and/or 
nonpathogenic mycobacteria including M. 
tuberculosis H37Ra, M. smegmatis, M. aurum
and others as test organisms. A group of 
research works includes investigations on M. 
tuberculosis clinical isolates and strains 
possessing multidrug resistance. Multidrug-
resistant tuberculosis (MDRTB) is strictly 
defined as M. tuberculosis strains showing 
resistance simultaneously against isoniazid
and rifampicin3,4. Tuberculosis with a different 
drug resistance (DDRTB) involves M. 
tuberculosis strains displaying mono- or 
polyresistance not including associated 
resistance against isoniazid and rifampicin5. 
Very recently, patterns of resistance to 
commonly used anti-tuberculosis drugs among
M. tuberculosis complex isolates from patients 
attending government urban TB diagnostic in 
Makassar, the capital of the South Sulawesi 
Province in Indonesia, was found to be highly 
potential risk factors for MDR-TB6. In order to 
tackle these new situations, it is necessary and 
important to develop not only new treatment 
guidelines, such as combination treatment 
between clinical drug with natural product 
compounds, but also new anti-mycobacterial 
drugs for efficacious clinical control of TB 
patients. On the other hand, the ocean 
environment contains over 80% of world’s plant 
and animal species7 and with more than 
150,000 seaweeds found in the intertidal zones
and tropical waters of the oceans, it is a 
primary source of natural products8. Research 
in natural products has given a number of 
drugs and recently a novel compound, isolated 
from marine algae was found to be active 
against MDR TB9,10. Considering the potential 
and biodiversity of natural flora in Indonesia 
especially marine algae, it is important to 
explore it for new drug prototypes for
tuberculosis diseases. In this work, we report 
for the first time the isolation, purification, and 
structural determination of triterpenoid 
carbocylic acid from red algae Euchema 
spinosum. We also tested the activity of 
triterpenoid carbocylic acid alone and in 
combination with the anti-tuberculosis drug 
isoniazid (INH) against M. tuberculosis strain 
H37Rv (ATCC 27294) to increase sensitivity to
anti-tuberculosis drugs.
MATERIAL AND METHODS
Materials
The red algae Euchema spinosum was 
collected in the region of Barang Lompo Island, 
South Sulawesi Province, Indonesian 
terrestrial. Algae  identification was conducted 
in Marine Biology Laboratory Faculty of Natural 
Sciences Hasanuddin University, Indonesia. 
Chloroform, isoniazid, and methanol were 
purchased from Sigma.
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Extraction and Isolation
Dry powder of 3.2 kg of algae was macerated 
with MeOH for 72 h, filtered, and solvent 
evaporated to obtain a dark brown extract 
amounting 312 g. The extracts were partitioned 
with chloroform resulting in 51 g product. The 
chloroform extract was fractionated by VLC 
and produced nine major fractions (I-IX). White 
precipitate found in the third fraction was 
filtered by filtration resulting in 49 mg product. 
Purity test was performed by TLC analysis
using three solvent systems and its melting 
point determined.
Instrumentation
The melting point was determined using a 
micro melting point measurement (John Fisher, 
Germany). IR spectra determination was done 
with a Shimadzu  spectrometer (Japan). NMR 
spectra of 1H, 13C and HMBC were obtained 
using a Bruker, Germany DPX-500 
spectrometer at 300 MHz (1H) and 125 MHz 
(13C) with TMS as an external standard. 
Separations and identification of compound 
were conducted with VLC by Merck Si gel 60 
(230-400 mesh), and TLC on aluminum or 
glass plates coated with Merck Si gel 60 F254 
and thickness of 0.25 mm.
Anti-mycobacterial  activity assays
For the initial bioactivity screening, standard 
colony assays on Löwenstein-Jensen (LJ) 
medium were performed to assess the anti-
mycobacterial activity of Methanol whole 
extract, chloroform fraction, and compound 1 
with the final concentrations of 10 µg/mL, 
respectively, using the strain M. tuberculosis
H37Rv (ATCC 27294) and solvent DMSO as 
negative control plus INH as positive control11.  
For testing the anti-mycobacterial activity of 
compound 1 and in combination with isoniasid,
the strain M. tuberculosis H37Rv (ATCC 
27294) were grown on Middlebrook 7H19-
OADC (oleic acid, albumin, dextrose, catalase) 
(Difco Laboratories, USA) at 37 °C for 3 weeks 
until midlog phase. The turbidity of culture were 
adjusted with 7H9 broth to a 0.5 McFarland 
standard using a nephelometer, and cell 
cultures   was  inoculated   on   4   mL  MGIT 
medium12, using solvent (DMSO) as negative 
control, isoniasid  (0.5 and 1.0 µg/mL), and 
combination with compound 1 were indicated. 
Tubes were incubated at 37 °C and inhibition 
growth documented after 3 days; MGIT tubes 
were removed from the incubator and placed 
on a 365 nm UV transilluminator (micro MGIT 
reader). It is important to read the tube every
day beginning on day 3, until results can be 
interpreted. The growth control tube was 
compared to the positive and negative controls; 
positivity was indicated by bright orange 
fluorescence on the bottom of the tube and an 
orange reflection at the meniscus; negative 
tubes on the other hand showed low level or no 
fluorescence. Once the MGIT growth control is 
positive, the drug-containing tubes will be read 
for interpreting results. The drug-containing 
tubes are interpreted on the same day the 
MGIT GC is positive and for up two additional 
day, not to exceed fourteen days. If the MGIT 
GC tube is not positive by the twelfth day of the 
test, the test is invalid. Interpret the MGIT 
result as susceptible if the drug-containing tube 
does not fluoresce within two days of onset of 
fluorescence in the GC tube. Interpret the 
MGIT result as resistant if the drug-containing 
tube fluoresces on or within two days of the 
day of onset of fluorescence in the GC tube. 
When interpreting resistance, finalize the result 
as soon as the MGIT GC and the drug-
containing tubes fluoresce. All inoculated MGIT 
tubes after 56 days or negative results should 
be autoclaved prior to disposal. For positive 
MGIT media results should add disinfectant 
(5 % Vesphene) before put in the autoclave 
bag. MGIT tubes are kept in the autoclave bag 
place in the autoclave. After finishing
autoclaving, send them for the incineration.
The growth control tube was compared to the 
positive and negative controls; positivity was 
indicated by bright orange fluorescence on the 
bottom of the tube and an orange reflection at 
the meniscus; negative tubes on the other 
hand showed low level or no fluorescence. The 
assays was conducted in duplicates and 
repeated three times to produce representative 
experimental data.
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RESULTS AND DISCUSSION
The methanol extract of the dried and 
powdered form of red algae Euchema 
spinosum was partitioned with chloroform. The 
chloroform fraction was further separated by 
silica gel chromatography and crystallized to 
obtain compound 1. The compound obtained, 
compound 1 is a white powder crystal, mp 176-
177 oC, giving an indication of triterpenoid on 
Liebermann-Burchard test. Its IR spectrum 
showed the absorption bands for hydroxyl
(1097), aliphatic groups (2962, 2918 and 
2850), C=C (1635), CH2 (1459), CH3 (1378), 
C=O (1705, 1072) and while strong absorption 
band at 1026 were characterized as a 
carbocylic acid compound11.
Table 1
1H (300 MHz) and 13C (125 MHz) NMR data of compound 1 in DMSO (TMS)
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Figure 1
Structure of triterpenoid carbocylic acid (1)
from red algae Euchema spinosum
The 13C NMR and DEPT spectrum exhibited 30 
carbon signals (7×CH3, 11×CH2, 4×CH, 8×C 
including COOH), and  the molecular formula 
of compound 1 was deduced to be C30H46O2. 
The 1H NMR spectrum (Table 1) observed the 
presence of seven tertiary methyl groups on 
saturated carbons at d 1.21(s, 3H), 0.89 (s, 
6H), 1.28 (s, 6H), 1.04 (s, 3H), 1.01 (s, 3H), 
which is due to the axial proton attached to C-4 
containing the methyl group, one olefinic 
proton appeared as a double doublet at d 1.78 
(dd, 1H, J=4.1, 8.2Hz). Two olefinic carbons at 
d 123.2 and 143.7 in the 13C NMR (Table 1) 
spectrum indicated that compound 1 belongs 
to the triterpenoid,  and the double bond C=C 
is at C-12 and C-13. The position of the 
carboxylic group at C-17 was confirmed by the 
HMBC spectrum (Figure 1). The correlation of 
C-28 (-COOH) with H2-16, H-18 and H-22 
were observed in the HMBC spectrum.  Based 
on the data description above and compared 
with physico-chemical and spectroscopic data 
of previously known compound13, the 
molecular structure of compound 1 is in Figure 
1 with name of triterpenoid carbocylic acid. In 
the first, antimycobacterial activity of all 
fractions, including compound 1 at 
concentrations 10 µg/mL  was measured by 
incubating with  the  mycobacterial cells on LJ 
medium. Methanol  fraction at concentration 
10 µg/mL was able to decrease mycobacterial 
cells growth, where as chloroform fraction and 
compound 1 in the same concentration, like 
INH as positive control with no colony growth 
of M. tuberculosis on LJ medium. However, 
negative control (DMSO) did not display anti-
mycobacterial activity (Figure 2). To confirm 
this finding and to identify the MIC value of 
Figure 2
Effect of  MeOH whole extract, chloroform fraction, and compound 
1 alone on growth inhibition of M. tuberculosis H37Rv (ATCC 27294)
strain in Löwenstein-Jensen medium
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compound 1,  anti-mycobacterial activity  of 
this compound  against M. tuberculosis test 
was performed with MGIT medium. The 
combinations of compound 1 and INH were 
tested in the anti-mycobacterial assay 
described above by a checkerboard method in 
order to identify those combinations that could 
enhance bioactivity effect. The anti-
mycobacterial activity of compound 1 at 
different concentrations 0, 0.5, 2, and 4 µg/mL  
in combination with INH at variation 
concentrations 0, 0.5, 1 µg/mL  was measured 
by incubating the mycobacterial cells on MGIT 
medium. Compound 1 alone at concentration 
0.5 and 2 µg/mL was able to decrease
mycobacterial cells growth. Furthermore, at  
concentration 4 µg/mL showed significant 
inhibition of growth of M. tuberculosis (Figure
3). This result was in accordance with 
previously reported research by Woldemichael
et al (2003), where terpenoid compounds from 
Calceolaria pinnifolia (Scrophulariaceae) 
showed significant inhibition of growth of M. 
tuberculosis with MIC values between 4 and 
128 µg/mL14.
Figure 3
Effect of compound 1 in combination with INH in MGIT medium on growth
inhibition of M. tuberculosis H37Rv (ATCC 27294) strain.
(A) Before  placed on a 365 nm UV transilluminator and  
(B) After placed on a 365 nm UV transilluminator
In addition, recently reported research by 
Truong et al (2011), that triterpenoid compound 
from Radermachera boniana  showed 
significant inhibition of growth of M. 
tuberculosis with MIC values 4 µg/mL15. The 
combinations with the INH drug at 
concentration 0.5 and 1 µg/mL could 
completely inhibit the cells at all concentration 
of compound 1, although mechanism of anti-
mycobacterial  action by direct and/or indirect  
of triterpenoid  has not been clear, but it is 
speculated that membrane disruption of 
mycobacterial cells by lipophilic compounds
involves in the mechanism16.
CONCLUSION
Compound 1, triterpenoid carbocylic acid was
isolated from red algae Euchema spinosum. 
The compound was not only active against M.
tuberculosis at 4 µg/mL, but also could 
increase the sensitivity of this pathogen to 
isoniasid drug. In conclusion, our results 
demonstrated that the activity isoniasid  drug 
could be enhanced through  triterpenoid 
carbocylic acid.  Further studies using in vivo
methods are required to explore the compound
responsible for the activity and the mechanism 
of this activity which might prove important for
improved therapies for the treatment and 
prevention of tuberculosis.
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